Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
OraSure Technologies senior vice president of finance and chief accounting officer Anthony Michele Marie reported routine equity compensation activity in common stock. On March 2, 2026, she received a grant of 42,982 shares of restricted stock that vest in three equal annual installments beginning on March 2, 2027, contingent on continued service.
On March 1, 2026, she acquired 14,183 shares in settlement of vested performance units, then had 4,062 shares and 10,817 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly held 185,788 shares of OraSure common stock.
OraSure Technologies received an amended Schedule 13D from Altai Capital, led by Rishi Bajaj, reflecting an activist position. The reporting persons beneficially own 3,613,836 shares of common stock, representing 5.2% of the company based on 69,126,173 shares outstanding as of February 28, 2026.
On March 17, 2026, Altai Capital’s investment manager issued a press release with an open letter to the board outlining its case for change and reiterating its intention to solicit proxies to elect Rishi Bajaj and John Bertrand at the annual meeting. The full letter is filed as Exhibit 99.3.
Altai Capital, a shareholder owning approximately
Altai requests a strategic review including consideration of a sale, seeks board seats for its nominees, and says it will solicit votes if no settlement is reached.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 22,021 shares of common stock. The shares were bought on
OraSure Technologies President & CEO Carrie Eglinton Manner purchased 22,022 shares of common stock in an open-market transaction at a weighted average price of $2.9985 per share.
The trade was executed under a pre-arranged Rule 10b5-1 trading plan, and following this purchase she directly owns 2,158,574 OraSure shares.
OraSure Technologies, Inc. details its diagnostics and sample management business in an annual report for the year ended December 31, 2025. The company develops rapid tests for HIV, hepatitis C, syphilis, Ebola, sickle cell and COVID-19, plus saliva, urine and microbiome collection systems sold globally to clinical, research and commercial customers.
In November 2025 OraSure acquired BioMedomics, adding the SickleSCAN rapid sickle cell test sold outside the U.S. The company is advancing new products, including a rapid molecular self-test for chlamydia and gonorrhea and an at-home Colli-Pee urine collection device for sexually transmitted infections, both with 510(k) submissions filed in December 2025 and under FDA review.
Revenue mix is shifting sharply as InteliSwab COVID-19 test sales fell from $257,493,000 in 2023 to $45,136,000 in 2024 and $620,000 in 2025, while OraQuick HIV revenue declined to $49,802,000 in 2025 and Genomics products to $31,546,000. A single non-commercial customer represented 63% of revenue in 2023, 24% in 2024 and about 3% in 2025, highlighting reduced concentration but significantly lower COVID-related volumes.
OraSure exited its substance abuse testing business, continues to invest in BARDA-supported Ebola and Marburg virus tests, and emphasizes intellectual property protection across its brands and collection technologies. As of December 31, 2025, the company employed 500 people and held an aggregate non‑affiliate market value of $218,472,693 as of June 30, 2025, with 69,126,173 common shares outstanding as of February 28, 2026.
OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.
The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported equity award activity in company stock. On March 1 and March 2, he acquired 88,348 and 26,814 shares of common stock at
OraSure Technologies President & CEO Carrie Eglinton Manner reported equity compensation and related tax withholding transactions in company common stock. On March 2, 2026, she received a grant of 355,464 shares of restricted stock that vest in three equal annual installments beginning March 2, 2027, conditioned on continued service.
On March 1, 2026, she acquired 129,032 shares delivered in settlement of vested performance units and had 56,116 and 122,655 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly owned 2,136,552 common shares.
OraSure Technologies reported sharply lower results for the quarter and year ended December 31, 2025 as COVID-related demand faded and core markets softened. Q4 2025 net revenues were $26.8 million, down 29% from $37.4 million a year earlier, and full-year revenues fell to $115.0 million from $185.8 million. The company posted a Q4 GAAP net loss of $19.3 million and a full-year loss of $68.7 million, with Q4 non-GAAP operating loss widening to $15.2 million. Despite the downturn, Q4 non-GAAP gross margin improved to 41.4% and cash and cash equivalents totaled $199 million with no debt.
Core revenues of $26.7 million in Q4 declined 22% year-over-year, driven by a 20% drop in diagnostics sales to $15.1 million and a 39% decline in Sample Management Solutions revenues to $9.1 million. COVID-19 revenues nearly disappeared, falling 95% in Q4 and 99% for the year. Management highlighted cost actions, site consolidations, product line closures, and a $40 million share repurchase program, of which $5 million was used in Q4 to buy back about 1.9 million shares. Looking ahead, the company is guiding Q1 2026 total revenues to $26–29 million and expects low‑40% non-GAAP gross margins, while banking on potential FDA clearances for a rapid molecular self‑test for chlamydia and gonorrhea and the Colli‑Pee urine collection device to help return the business to growth.